Sponsor: NRG Oncology Foundation
Sponsor Study ID: NRG-GU011
Study Title: NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy With Or Without Androgen Deprivation Therapy In Oligometastatic Prostate Cancer (NRG PROMETHEAN)
CTO #: 104168
NCT Number:
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Prostate
Study Objectives: Compare conventional radiological progression-free survival (rPFS) for positron emission tomography (PET) detected, biochemically recurrent, oligometastatic, castration- sensitive prostate cancer patients treated with SABR plus placebo vs. SABR plus relugolix.